Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN 7% (PH6) vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and metabolic processes, providing essential and non-essential amino acids for tissue repair and maintenance.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
AminoSyn 7% (pH 6) is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1.0-1.5 g amino acids/kg/day, infused at a rate not exceeding 0.1 g amino acids/kg/hour. The infusion rate and volume are determined by the patient's metabolic needs, clinical status, and concurrent dextrose and lipid administration.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
The elimination half-life of individual amino acids varies, typically 0.5-2 hours for most, reflecting rapid incorporation into metabolic pools. For total amino acid mixture, functional half-life is approximately 1-2 hours in patients with normal hepatic and renal function.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Amino acids in Aminosyn 7% (pH6) are primarily metabolized; excess nitrogen is excreted renally as urea. Approximately 80-90% of infused amino acids are utilized for protein synthesis or metabolized; remaining nitrogen is eliminated as urea via kidneys. Biliary and fecal elimination are negligible.
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution